Extracellular Vesicle, Год журнала: 2024, Номер 4, С. 100054 - 100054
Опубликована: Окт. 23, 2024
Язык: Английский
Nature Communications, Год журнала: 2023, Номер 14(1)
Опубликована: Авг. 7, 2023
Extracellular vesicles (EVs) are gaining ground as next-generation drug delivery modalities. Genetic fusion of the protein interest to a scaffold with high EV-sorting ability represents robust cargo loading strategy. To address paucity such proteins, we leverage simple and reliable assay that can distinguish intravesicular proteins from surface- well non-vesicular compare potential 244 candidate proteins. We identify 24 conserved abilities across five types producer cells. TSPAN2 TSPAN3 emerge lead candidates outperform well-studied CD63 scaffold. Importantly, these engineered EVs show promise vehicles in cell cultures mice demonstrated by efficient transfer luminal surface display different functional entities. The discovery scaffolds provides platform for EV-based engineering.
Язык: Английский
Процитировано
34
ACS Nano, Год журнала: 2025, Номер unknown
Опубликована: Янв. 27, 2025
Extracellular vesicles (EVs) are cell derived nanovesicles which implicated in both physiological and pathological intercellular communication, including the initiation, progression, metastasis of cancer. The exchange biomolecules between stromal cells cancer via EVs can provide a window to monitor development real time for better diagnostic interventional strategies. In addition, process secretion internalization by tumor microenvironment (TME) be exploited delivering therapeutics. have potential targeted, biocompatible, efficient delivery platform treatment other diseases. Natural as well engineered nanomedicine immense disease intervention. Here, we an overview current knowledge EVs' function therapeutic applications setting, EV engineering
Язык: Английский
Процитировано
1
Advanced Drug Delivery Reviews, Год журнала: 2024, Номер unknown, С. 115461 - 115461
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
4
Extracellular Vesicle, Год журнала: 2025, Номер 5, С. 100065 - 100065
Опубликована: Янв. 22, 2025
Язык: Английский
Процитировано
0
Nature Reviews Bioengineering, Год журнала: 2025, Номер unknown
Опубликована: Март 17, 2025
Язык: Английский
Процитировано
0
Cytotherapy, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Oncogene, Год журнала: 2025, Номер unknown
Опубликована: Март 28, 2025
ncRNAs encapsulated in small extracellular vesicles (sEVs) facilitate intercellular communication and are associated with tumor progression. lncRNA-HOTAIRM1 is aberrantly expressed various cancers. However, HOTAIRM1 expression its downstream ceRNA network CTCL remains unclear. In this study, we found that was reduced CTCL. Elevated inhibited proliferation induced apoptosis vitro, resulting vivo tumorigenic capacity. Whole-transcriptome sequencing scRNA-Seq confirmed differential of HOTAIRM1/miR-196b-5p/MGAT4A axis induces resistance Mechanistically, MGAT4A leads to decreased N-glycosylation modification membrane proteins Galectin-1 affinity, thereby inducing partial Galectin-1-induced apoptosis. Meanwhile, benign CD4 + T cells show sensitivity due their relatively higher expression. Furthermore, MGAT4ALow transformed MGAT4AHigh CD4+ into by secreting sEVs containing miR-196b-5p, reducing binding resistance. Engineered from HOTAIRM1-overexpressing contain elevated HOTAIRM1, which can specifically target malignant cells, miR-196b-5p increased MGAT4A, demonstrating apoptosis-inducing tumor-suppressive effects This study identified changes modifications HOTAIRM1-loaded demonstrated promising targeting therapeutic
Язык: Английский
Процитировано
0
Extracellular Vesicle, Год журнала: 2024, Номер 4, С. 100054 - 100054
Опубликована: Окт. 23, 2024
Язык: Английский
Процитировано
1